M3 (2413) Q4 2026 earnings summary

Executive summary

• Achieved record-high operating profit in FY2025, surpassing the COVID-19 demand peak, with double-digit growth in both revenue and profit year-over-year.

• Growth was driven by strong performance across core segments, new acquisitions, and expansion in both domestic and overseas markets.

• AI advancements are driving operational efficiency, value creation, and platform strength, with minimal negative impact on core businesses.

• Updated group mission to emphasize creative technology use, including AI, to improve health outcomes and reduce costs.

Financial highlights

• FY2025 revenue: JPY 351,363MM (+23% YoY); operating profit: JPY 73,547MM (+17% YoY); net profit: JPY 54,046MM (+22% YoY); profit before tax: JPY 76,276MM (+18% YoY).

• Operating profit margin was 20.9%.

• Basic earnings per share increased to ¥72.53 from ¥59.62 year-over-year.

• Cash and cash equivalents at period end were ¥156,177 million, up from ¥134,933 million.

• Recognized JPY 6.7Bn impairment losses, mainly in overseas segments.

Outlook and guidance

• FY2026 outlook expects continued growth, driven by ecosystem expansion, business development, and AI synergy.

• No new acquisitions planned for FY2026; focus on organic growth and digital transformation.

• Pharma marketing support and clinic DX expected to be key growth drivers.

• Fiscal year ending March 31, 2027, revenue is forecast to grow 13.8% to ¥400,000 million, with operating profit up 8.8% to ¥80,000 million.

• Net profit attributable to owners is projected to rise 7.9% to ¥53,000 million, with EPS of ¥78.29.